Rotstein S, Blomgren H, Nilsson B, Petrini B, Wasserman J, Baral E
Chemioterapia. 1984 Aug;3(4):227-31.
Eighty-three patients, operated for carcinoma of the breast, received adjuvant therapy with chlorambucil, methotrexate and 5-fluorouracil or cyclophosphamide, methotrexate and 5-flourouracil. This group was subjected to a study exploring prognostic value, as defined by disease-free survival, of some immune variables. These included numbers of blood lymphocytes expressing membrane receptors for sheep erythrocytes (mainly T-cells), receptors for C'3 (mainly B-cells) and proliferative responses of the cells to phytohemagglutinin, purified protein derivative of tuberculin and in a mixed lymphocyte culture. Follow-up time was 30-71 months after start of adjuvant therapy. None of these variables showed any significant relation to prognosis in the present patient material. In addition, there was no detectable relation between numbers of eosinophils in the blood and disease-free survival. The well-known importance of tumor size and/or involvement of axillary nodes was, however, confirmed.
83例接受乳腺癌手术的患者接受了苯丁酸氮芥、甲氨蝶呤和5-氟尿嘧啶或环磷酰胺、甲氨蝶呤和5-氟尿嘧啶的辅助治疗。该组患者接受了一项研究，探讨一些免疫变量（以无病生存期定义）的预后价值。这些变量包括表达绵羊红细胞膜受体的血液淋巴细胞数量（主要是T细胞）、C'3受体数量（主要是B细胞）以及细胞对植物血凝素、结核菌素纯蛋白衍生物和混合淋巴细胞培养的增殖反应。随访时间为辅助治疗开始后的30至71个月。在本患者材料中，这些变量均未显示出与预后有任何显著关系。此外，血液中嗜酸性粒细胞数量与无病生存期之间没有可检测到的关系。然而，肿瘤大小和/或腋窝淋巴结受累的众所周知的重要性得到了证实。
